Literature DB >> 2574051

A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonist.

G Acton1, C Broom.   

Abstract

1. SK&F 101468, a non phenolic indolone derivative, has been characterised preclinically as a novel, potent and specific dopamine D2-receptor agonist. 2. Its tolerability and effects on serum prolactin were investigated in 14 healthy male volunteers in a study of the first administration of SK&F 101468 to man. 3. Doses between 80 micrograms and 2.5 mg caused statistically significant (P less than 0.05) lowering of basal and food stimulated serum prolactin, relative to placebo, over a 6 h post treatment period. 4. SK&F 101468 was well tolerated up to 1 mg with symptoms of nausea and postural hypotension at higher doses.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2574051      PMCID： PMC1379994          DOI： 10.1111/j.1365-2125.1989.tb03524.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  25 in total

Review 1.  Role of brain monoamines and histamine in regulation of anterior pituitary secretion.

Authors:  R I Weiner; W F Ganong
Journal:  Physiol Rev       Date:  1978-10       Impact factor: 37.312

Review 2.  Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system.

Authors:  J L Willems; W A Buylaert; R A Lefebvre; M G Bogaert
Journal:  Pharmacol Rev       Date:  1985-06       Impact factor: 25.468

Review 3.  Bromocriptine.

Authors:  D Parkes
Journal:  Adv Drug Res       Date:  1977

Review 4.  Area postrema: chemoreceptor trigger zone for vomiting--is that all?

Authors:  H L Borison
Journal:  Life Sci       Date:  1974-05-16       Impact factor: 5.037

5.  The inhibitory effect of an ergoline derivative (lergotrile, compound 83636) on prolactin secretion in man.

Authors:  L Lemberger; R Crabtree; J Clemens; R W Dyke; R T Woodburn
Journal:  J Clin Endocrinol Metab       Date:  1974-09       Impact factor: 5.958

6.  Monoamine fluorescence histochemistry of human post mortem brain.

Authors:  L Olson; B Nyström; A Seiger
Journal:  Brain Res       Date:  1973-12-07       Impact factor: 3.252

7.  Prevention or reversal of levodopa-induced cardiac arrhythmias by decarboxylase inhibitors.

Authors:  L C Parks; A M Watanabe; I J Kopin
Journal:  Lancet       Date:  1970-11-14       Impact factor: 79.321

8.  4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone: a prejunctional dopamine receptor agonist.

Authors:  G Gallagher; P G Lavanchy; C A Webster; J W Wilson; J P Hieble; R M DeMarinis
Journal:  J Med Chem       Date:  1985-10       Impact factor: 7.446

9.  Domperidone antagonizes bromoergocriptine--induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women.

Authors:  C Nappi; G Colace; G F Di Renzo; M Taglialatela; S Amoroso; L Annunziato; U Montemagno
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].

Authors:  W BIRKMAYER; O HORNYKIEWICZ
Journal:  Wien Klin Wochenschr       Date:  1961-11-10       Impact factor: 1.704
View more
  7 in total

1.  Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist.

Authors:  C de Mey; D Enterling; I Meineke; S Yeulet
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of ropinirole.

Authors:  C M Kaye; B Nicholls
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

3.  Methylphenidate decreases the EEG mu power in the right primary motor cortex in healthy adults during motor imagery and execution.

Authors:  Danielle Aprigio; Juliana Bittencourt; Mariana Gongora; Victor Marinho; Silmar Teixeira; Victor Hugo Bastos; Mauricio Cagy; Henning Budde; Pedro Ribeiro; Luis Fernando Basile; Bruna Velasques
Journal:  Brain Struct Funct       Date:  2021-02-17       Impact factor: 3.270

4.  A comparison of the neuro-endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers.

Authors:  P de Koning; M H de Vries
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

5.  Pharmacokinetics and pharmacodynamics of ropinirole in patients with prolactinomas.

Authors:  Sihang Liu; Can Hu; Jane Peters; Amanda Tsang; Serge Cremers; Robert Bies; Gabrielle Page-Wilson
Journal:  Br J Clin Pharmacol       Date:  2018-11-22       Impact factor: 4.335

6.  Update on ropinirole in the treatment of Parkinson's disease.

Authors:  Holly A Shill; Mark Stacy
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

7.  Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).

Authors:  Satoru Morimoto; Shinichi Takahashi; Komei Fukushima; Hideyuki Saya; Norihiro Suzuki; Masashi Aoki; Hideyuki Okano; Jin Nakahara
Journal:  Regen Ther       Date:  2019-07-26       Impact factor: 3.419
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.